ReviewAntidepressant medications and osteoporosis
Highlights
► Current use of selective serotonin reuptake inhibitors (SSRIs) and tricyclics increases fracture risk. ► The increase in risk is the greatest in the early stages of treatment. ► Treatment-associated increased risk diminishes in the year following discontinuation. ► SSRIs should be considered in the list of medications that are risk factors for osteoporotic fractures.
Introduction
Serotonin is well known as a regulator of mood. An increase in synaptic availability of serotonin is known to have an antidepressant effect, and is involved in all or part of the mechanism of action of some of the most widely used antidepressants. However, serotonin also plays an important role centrally in functions such as appetite, sleep, sex, and temperature, and acts peripherally in the cardiovascular and gastrointestinal systems. There is increasing evidence that serotonin may also be an important regulatory agent in bone metabolism [1], notably bone mass.
Antidepressant treatments that act on serotonin pathways may therefore be expected to have some impact on bone, bone mass, and fracture rates. The link between depression, antidepressant use, and osteoporosis is becoming more widely understood, and there is mounting evidence for an effect of depression and antidepressants on fracture rates. This article was prepared by a working group of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), which reviewed the evidence for an effect of antidepressants on bone mass and fracture, as well as the impact of various confounders, including depression itself.
Section snippets
Methods
Relevant articles, reviews, and abstracts were identified through a PubMed/MEDLINE search of English-language articles published between 1990 and September 2011. The search strategy included the terms antidepressant, serotonin, selective serotonin reuptake inhibitor (SSRIs, fluoxetine, paroxetine, citalopram, escitalopram, sertraline, and fluvoxamine), serotonin and noradrenaline reuptake inhibitor (SNRIs, venlafaxine and duloxetine), tricyclic antidepressants (amitriptyline, clomipramine,
Serotonin and bone pathophysiology
Serotonin (5-hydroxytryptamine, 5-HT) is synthesized in the gut and the brain from tryptophan via the enzyme tryptophan hydroxylase (TPH) [1]. More than 95% of human serotonin is synthesized in the gut (i.e. the duodenum) by enterochromaffin cells via the TPh1 isoform of the enzyme. Gut-derived serotonin is for the most part stored in platelets, and it plays a role in platelet aggregation and blood clotting after injury. The rest of human serotonin (< 5%) is produced in the brainstem, also from
Depression and antidepressants
Depression is a major public health problem and a leading cause of disability. Epidemiological studies suggest that the prevalence of some form of depression is about 22% in the US population, with substantially higher rates in women (26%) than in men (18%) [13]. The lifetime prevalence of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders IV [DSM-IV] criteria) is estimated at 16% [14]. Similar rates of depression are reported in European populations [15].
According
Depression and risk for fracture
Before considering the impact of any pharmacological modification of the serotonin system on bone, it is necessary to understand the impact of depression itself on bone health. The association between depression and fracture has been known since the late 1990s, and has been the subject of a number of studies. For instance, a prospective study in 7414 elderly white women with depression showed that the presence of depression increased the risk for nonvertebral fracture (adjusted hazard ratio
Antidepressants and BMD
The impact of antidepressants on fracture may be linked to the effects on BMD [28], [29]. There have been a number of cross-sectional and cohort studies exploring the relationship between the use of antidepressants and BMD (Table 3) [30], [31], [32], [33], [34], [35], [36]. A population-based cohort study in 5000 adults reported a significant reduction in hip BMD (− 4%, 95% confidence interval [CI], − 6.6% to − 1.4%) in SSRI users versus nonusers, and a trend towards a reduction in spine BMD (−
Antidepressants and risk for fracture
The association between antidepressants and fracture has been the subject of a number of observational studies, generally with case–control or cohort designs (Table 4) [27], [34], [35], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56]. The results indicate that current use of SSRIs and tricyclics increases the risk for fracture by as much as twofold versus nonusers. Although there is some variation between the studies, the ORs for increases in
Discussion
There is a complex interaction between depression, the drugs used to treat depression, and osteoporosis. To summarize, patients with depression may have decreased BMD [20], [22], though not all studies have agreed on this finding [21]. This decrease in BMD may be associated with an increased rate of fracture, though part of this elevated risk appears to be independent of BMD, perhaps through increased frequency of falls. The management of depression with antidepressant medications such as SSRIs
Conflict of interest statements
B. Abrahamsen: paid advisory boards for Amgen and Nycomed. Research support from Novartis, NPS Pharmaceuticals, and Amgen. Speakers fees Nycomed, Merck, Eli Lilly, and Amgen. Consulting fees Merck, Sharp and Dohme. J.R. Adachi: consulting and/or speaker fees for Amgen, Eli Lilly, GSK, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi Aventis, and Warner Chilcott. Research funding (clinical trials) from Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Procter & Gamble,
Acknowledgments
This paper was derived from a Working Group meeting on 22 September 2011 supported by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
References (64)
- et al.
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum
Cell
(2008) - et al.
A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure
Cell
(2009) - et al.
Leptin regulates bone formation via the sympathetic nervous system
Cell
(2002) - et al.
Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study
Eur Psychiatry
(2008) - et al.
SSRIs, bone mineral density, and risk of fractures—a review
Eur Neuropsychopharmacol
(2009) - et al.
The adverse skeletal effects of selective serotonin reuptake inhibitors
Eur Psychiatry
(2012) - et al.
Lithium's effect on bone mineral density
Bone
(2009) - et al.
Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people
Lancet
(1998) - et al.
Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures
Bone
(2010) - et al.
Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?
Bone
(2010)
Update in serotonin and bone
J Clin Endocrinol Metab
The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis
Clin Chem
The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice
J Musculoskelet Neuronal Interact
LRP5, Serotonin, and bone: complexity, contradictions, and conundrums
J Bone Miner Res
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis
Nat Med
Lrp5 functions in bone to regulate bone mass
Nat Med
Depression induces bone loss through stimulation of the sympathetic nervous system
Proc Natl Acad Sci U S A
Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth
Endocrinology
Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency
Menopause
Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008
J Am Board Fam Med
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)
JAMA
Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatr Scand Suppl
Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database
BMJ
Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group
Arch Intern Med
Depressive symptoms and rates of bone loss at the hip in older women
J Am Geriatr Soc
Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong)
Osteoporos Int
Depression in anorexia nervosa: a risk factor for osteoporosis
J Clin Endocrinol Metab
Depression and bone mineral density in young adults: results from NHANES III
Psychosom Med
Depression and osteoporosis: epidemiology and potential mediating pathways
Osteoporos Int
Depression and osteoporosis: a research synthesis with meta-analysis
Horm Metab Res
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Osteoporos Int
Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression
Intern Emerg Med
Cited by (144)
Incidence of Sacroiliac Joint Pain Following Lumbar Fractures: A Retrospective-Cohort Study
2024, World NeurosurgeryProspective Association Between the Dispensing of Antidepressants and of Medications to Treat Osteoporosis in Older Age
2024, American Journal of Geriatric PsychiatryRisk of developing avascular necrosis of the femoral head and neck among patients with bipolar disorder: A nationwide cohort study
2023, European Journal of PsychiatryRole of biophysical stimulation in multimodal management of vertebral compression fractures
2023, Computational and Structural Biotechnology Journal